Table 1. Recommendations for monitoring of prostate cancer patients on active surveillance.

Guideline	Year	PSA	DRE	Rebiopsy	Biomarkers	MRI
NCCN (14)	2016	Q6 mo*	Q12 mo*	Q12 mo*	Not mentioned	Can be considered
AUA (20)	2007	Not mentioned explicitly	Not mentioned explicitly	Not mentioned explicitly	Not mentioned explicitly	Not mentioned explicitly
ASCO (21)	2016	Q3–6 mo	Q12 mo	At 6–12 mo after diagnosis, then q2–5 years	Can be considered, particularly for low-volume GS 7 disease	Can be considered; not a replacement for biopsy

*, can be less frequent if desired. PSA, prostate-specific antigen; DRE, digital rectal exam; MRI, magnetic resonance image; NCCN, National Comprehensive Cancer Network; mo, months.